Oncology Business Management | Specialty

Novel Strategies for Treatment of Early Breast Cancer, Part II

October 25th 2012

Novel Strategies for Treatment of Early Breast Cancer, Part I

October 25th 2012

Anthracyclines for Early-Stage HER2-Positive Breast Cancer

October 25th 2012

Hormonal and HER2-Targeted Therapy in Early Breast Cancer

October 25th 2012

Potential Biomarker for Response to Bevacizumab in Colorectal Cancer Identified

October 25th 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Accountable Care Organizations Come to Oncology

October 17th 2012

Integrative model unites physicians, hospitals, and payers to deliver evidence-based care and control cancer costs.

Drug Shortages Frustrate Nurses and Jeopardize Patient Care

October 15th 2012

The promise of a solution somewhere on the horizon for America's drug shortages isn't enough for the registered nurse who navigates shortages every day.

FDA Approves Nab-Paclitaxel for Advanced Lung Cancer

October 12th 2012

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

Dr. Petrylak on Enzalutamide's Role in Prostate Cancer

October 9th 2012

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Oncologist Practice Consolidation Continues

October 9th 2012

Driven by changes in reimbursement and standards of care, independent community oncology practices continue to dwindle.

Are Physicians Drowning?

October 4th 2012

As with most industries where outcome metrics are crucial for continued success, the government is wanting physicians to deliver care that is outcome- and evidence-based.

Lessons on Patient Care Learned at Home

September 28th 2012

This fellow shares the insights he’s gained from his wife, a pediatric oncology nurse, and how they help in the care he provides.

Biomarker Predicts Survival Benefit in Advanced Kidney Cancer Treated With TORC1 Inhibitor

September 26th 2012

Pretreatment serum lactate dehydrogenase is a prognostic factor in poor-risk patients with renal cell carcinoma and also a predictive factor for a survival benefit from treatment with temsirolimus.

The Affordable Care Act: An Analysis of Its Impact on Urology Practices

September 20th 2012

For those of us with administrative responsibilities in large urology groups, the dilemma is amplified by the fact that we are affected not only as providers of care but as employers.

The CMS Fee Schedule: Impact on Oncology

September 18th 2012

There are several issues in the Centers for Medicare & Medicaid Services 2012 fee schedule that are of concern to oncologists.

Three Case Studies Highlight the Changing World of Oncology Practice

September 13th 2012

The economics of running an oncology practice is forcing physicians to consider whether they should stay in private practice, join a large network or hospital, or become hospital employees.

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

September 12th 2012

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Dr. Gandara on Patient Selection for Molecular Testing

September 12th 2012

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Enzalutamide Approved for Late-Stage Prostate Cancer

August 31st 2012

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

Targeted PD-1 Therapy Offers Opportunity to Sequence Agents

August 30th 2012

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.